Vertex Pharmaceuticals (VRTX) has done well to help many patients in the cystic fibrosis (CF) community. The problem is that it has more patients to cover and to potentially improve treatment upon. Well, it has generated another partnership with Moderna (MRNA) for developing a potential gene editing therapy for the treatment of patients with cystic fibrosis. This is the second collaboration that provides an additional shot on goal. I believe this is a good move for Vertex as it looks to expand its presence in the CF space. It is imperative that Vertex moves to do this to address the patients that don't respond to its current therapies. Since Vertex's CFTR modulators only target those CF patients who produce the CFTR protein, about 10% don't respond to its drugs. A mode of action of developing a gene-edited therapy to address this issue is plausible. That's why I believe Vertex has the potential to eventually expand its market with this latest deal. There was another deal made with Moderna years earlier that is also progressing as well. This is why I think it's worth a look as a speculative investment.
Vertex Pharmaceuticals and Moderna Pharmaceuticals made an agreement, whereby Moderna would use its lipid nanoparticle (LNP) technology to develop gene-edited therapies to treat patients with cystic fibrosis. This is not a bad agreement at all. That's because Vertex is only paying $75 million upfront for this collaboration and then up to $380 million in additional milestone payments. This means Moderna will be responsible for starting off research activities of its LNP technologies to hopefully make something suitable to bring into the clinic in human testing. Vertex will help a little bit in the research by providing gene editing that is supposed to be incorporated into the LNPs being developed. This isn't the only deal that Vertex made to advance another potential CF drug. Back in 2016, Vertex made another deal, whereby Moderna would use its mRNA technology to deliver a gene-edited therapy for the treatment of patients with CF. This other deal was a multi-year agreement with a $20 million upfront payment and then $20 million in a Moderna convertible note that was to be converted to equity. From there, it would be about $275 million in milestone payments. The bottom line here is that there are two delivery approaches being made to deliver gene-edited therapies. Both LNP and mRNA have the potential to deliver the gene that CF patients need to develop the CFTR protein. As I noted in the beginning, despite several CFTR modulators that Vertex markets, there are 10% of patients who don't benefit at all from them. That means these gene-edited therapies may potentially allow these nonresponder patients to respond.
According to the 10-Q SEC Filing, Vertex Pharmaceuticals had cash, cash equivalents, and marketable securities of $5.5 billion as of June 30, 2020. It has a huge cash runway to fund its pipeline and meet its commitments. Not only that, but I don't foresee the need to also do a major cash raise. The reason why is that, if necessary, it can tap into a revolving credit facility that was done in 2019. That is, it can borrow up to $500 million according to this agreement. There are several benefits here with this agreement that are also a huge plus. This includes the ability to repay and reborrow without penalty. In addition, if it is ultimately needed, Vertex can ask the borrowing capacity to be increased by another $500 million. That would bring the possible borrowing power to $1 billion. Of course, that's only an option if Vertex really needs additional cash. However, Vertex is already producing substantial amounts of revenue. For its Q2 of 2020 earnings, it reported product revenues of $1.52 billion. That's substantial because that is a 62% increase compared to the same time period in 2019. That is not the only thing that should give investors confidence. Another positive development is that the company raised its full-year 2020 guidance higher. It originally was expecting full-year 2020 CF revenues of $5.3-5.6 billion. However, with increasing sales, it is now guiding its full-year 2020 CF revenues to be $5.7-5.9 billion.
The latest collaboration agreement between Vertex and Moderna is still risky. That's because this is only starting off in the research phase and where preclinical studies must be done first in animal testing. There is no guarantee that any candidate/s will make it to human clinical testing. If that happens, then it's possible that either the first or second collaboration agreement could be terminated. The good news is that there are two routes that will be attempted. One route is to use LNPs to deliver gene-edited CFTR protein and then the other one will use messenger RNA (mRNA) delivery technology instead. As long as one delivery tech candidate is successful, that will be good news for both patients and investors. On the flip side, as I have shown, Vertex is already producing substantial revenues from its currently marketed CFTR modulator drugs. A second risk could be an eventual slowdown in revenues because of the situation with Covid-19; however, that hasn't had a dramatic impact on sales as of yet.
Vertex Pharmaceuticals is a good buy based on its recent performance in sales. As noted above, sales year over year in Q2 2020 increased by 62% to $1.52 billion. Not only that but guidance was also increased as well. The recent deal with Moderna, plus the one made several years ago, has the potential to help the company expand its presence in the CF space. While many benefit from Vertex's CFTR modulator drugs currently available, there are many who still don't. Even then, the company is also expanding its current CFTR modulator therapies to other subpopulation of patients. For example, it recently received FDA approval of KALYDECO for use in CF patients who are aged 4 to less than 6 months that have at least 1 mutation in their CFTR gene. KALYDECO was already approved for use in the U.S. and EU in CF patients, however, that was for patients aged 6 months and older. This latest regulatory approval will allow Vertex to treat an additional group of patients it couldn't target before. For all these reasons, that's why I think Vertex is worth a look as a speculative buy.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Read more from the original source:
- About Cystic Fibrosis | CF Foundation [Last Updated On: June 10th, 2016] [Originally Added On: June 10th, 2016]
- Cystic fibrosis - Wikipedia, the free encyclopedia [Last Updated On: June 10th, 2016] [Originally Added On: June 10th, 2016]
- cf. - Wikipedia, the free encyclopedia [Last Updated On: June 16th, 2016] [Originally Added On: June 16th, 2016]
- CF - Definition by AcronymFinder [Last Updated On: July 3rd, 2016] [Originally Added On: July 3rd, 2016]
- Cf Indus Hldgs - CF - Stock Price Today - Zacks [Last Updated On: August 12th, 2016] [Originally Added On: August 12th, 2016]
- Cf. - Wikipedia [Last Updated On: October 27th, 2016] [Originally Added On: October 27th, 2016]
- Technicals in Focus for CF Industries Holdings, Inc. (CF) - The USA Commerce [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- Real Madrid CF still on top of La Liga as Villarreal hold Sevilla to a draw - Hindustan Times [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- Black Heart Bart heads Weir's CF Orr Stakes nominations - HorseRacing.com.au [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- One Simple Thing Reg CF Issuers Can Do To Raise More Money Crowdfunding - Crowdfund Insider [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- Analysts Valuations For 2 Stocks: CF Industries Holdings, Inc. (NYSE:CF), Nordstrom, Inc. (NYSE:JWN) - The Voice Registrar [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- Andrew McCutchen to Move from CF to RF in 2017: Latest Comments and Reaction - Bleacher Report [Last Updated On: February 6th, 2017] [Originally Added On: February 6th, 2017]
- Basic Materials Stocks To Look Out For: Range Resources Corporation (RRC), CF Industries Holdings, Inc. (CF) - The Independent Republic [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- Here's Why CF Industries Stock Gained 10.7% in January - Motley Fool [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- Canyon releases lightweight Ultimate EVO CF 10.0 SL - Cyclingnews.com [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- How Does CF Industries Holdings, Inc. (CF) Stack Up Right Now? - StockNewsJournal [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- CF Orr Stakes - An Early Look - Racing.com [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- Own a Piece of the Pot: Fundanna is First Reg CF Crowdfunding Portal for Cannabis Industry - Crowdfund Insider [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- LaLiga: Valencia CF on the brink of a civil war - Yahoo Sports [Last Updated On: February 9th, 2017] [Originally Added On: February 9th, 2017]
- CF Orr Stakes day Caulfield racing preview - The Sydney Morning Herald [Last Updated On: February 9th, 2017] [Originally Added On: February 9th, 2017]
- CF Industries Holdings, Inc. Declares Quarterly Dividend - Business Wire (press release) [Last Updated On: February 9th, 2017] [Originally Added On: February 9th, 2017]
- CF Athletic and Cage Warriors Announce Exclusive Long-Term Apparel Partnership Deal - PR Newswire (press release) [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Gallery: Tiago Machado's Canyon Aeroad CF SLX - BikeRadar.com [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- CF man pleads guilty to role in Eagle Point murder - Eau Claire ... - Leader-Telegram [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Cystic Fibrosis - National Library of Medicine - PubMed Health [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- CF - CF Industries Holdings Inc Stock quote - CNNMoney.com [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Cystic Fibrosis | CF | Cystic Fibrosis Symptoms | MedlinePlus [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Why Investors remained confident on Paycom Software, Inc. (PAYC), CF Industries Holdings, Inc. (CF)? - StockNewsJournal [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- Two Canadian CF-18s were on approach to land at Florida airport ... - National Post [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- CF. Goldman Fall 2017 - WWD [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- CF Industries to Announce Its 4Q16 Earnings: What to Expect - Market Realist [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- Man steals $237 champagne from CF liquor store, police respond ... - Chippewa Herald [Last Updated On: February 12th, 2017] [Originally Added On: February 12th, 2017]
- CF Orr Stakes Where To Next - Racing.com [Last Updated On: February 12th, 2017] [Originally Added On: February 12th, 2017]
- Chainfire updates CF.lumen, Recently apps with Nougat-specific updates - Android Community [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- Real Madrid Castilla 2-1 CF Fuenlabrada: Match Review ... - Managing Madrid [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- CF Industries' Rally Just Starting to Grow - TheStreet.com [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- U-CF School Board adds new member and approves preliminary budget - Chester County Press [Last Updated On: February 14th, 2017] [Originally Added On: February 14th, 2017]
- Tiago Machado's Canyon Aeroad CF SLX Gallery - Cyclingnews.com [Last Updated On: February 14th, 2017] [Originally Added On: February 14th, 2017]
- Agriculture Stocks Feb 15 Earnings Roster: ANDE, BG, CF - Zacks.com [Last Updated On: February 14th, 2017] [Originally Added On: February 14th, 2017]
- CF Industries Holdings, Inc. (CF) Shares Bought by FIL Ltd - The Cerbat Gem [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- CF Industries' 4Q16 Profitability Disappointed Investors - Market Realist [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- CF Industries Holdings (CF) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Op/Ed: Sanville wrong for U-CF - Chadds Ford Live [Last Updated On: February 18th, 2017] [Originally Added On: February 18th, 2017]
- Canyon Ultimate CF Evo 10.0 SL review - BikeRadar - BikeRadar.com [Last Updated On: February 18th, 2017] [Originally Added On: February 18th, 2017]
- Kansas City Royals: Yost Plans To Use Alex Gordon In CF - Call to the Pen [Last Updated On: February 19th, 2017] [Originally Added On: February 19th, 2017]
- CF Industries (CF) Q4 Loss Wider than Expected, Sales Miss - Zacks.com [Last Updated On: February 19th, 2017] [Originally Added On: February 19th, 2017]
- Father's death, mother's strength inspire Tigers CF Mikie Mahtook - Detroit Free Press [Last Updated On: February 19th, 2017] [Originally Added On: February 19th, 2017]
- CF Rayo Majadahonda 0-1 Real Madrid Castilla - Managing Madrid [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- GridShare Targets Renewable Energy Crowdfunding under Reg CF, Plans International Expansion - Crowdfund Insider [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- CF group claims new data supports case for Orkambi approval - Irish Times [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- Cleveland Indians: Brandon Guyer To See Time In CF - Factory Of Sadness [Last Updated On: February 22nd, 2017] [Originally Added On: February 22nd, 2017]
- KC Royals: Alex Gordon CF Trial Suggests Worry About Lorenzo Cain - Kings of Kauffman [Last Updated On: February 22nd, 2017] [Originally Added On: February 22nd, 2017]
- CF Foundation lands big gift - Ocala [Last Updated On: February 22nd, 2017] [Originally Added On: February 22nd, 2017]
- Just the Facts on CF Industries Holdings, Inc. (CF) - StockNewsJournal [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- CF Industries Holdings, Inc. to Participate in Upcoming Investor Conference - Yahoo Finance [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 - P&T Community [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- Nivalis Therapeutics (NVLS) Says Cavosonstat Phase 2 Clinical ... - StreetInsider.com [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- Pawtucket man arrested for narcotics in CF - WPRI 12 Eyewitness News [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- Limerick CF parents: 'Our kid's lives are priceless' - Limerick Leader [Last Updated On: February 25th, 2017] [Originally Added On: February 25th, 2017]
- Real Madrid CF battle back to win at Villarreal CF and stay on top of La Liga - Hindustan Times [Last Updated On: February 26th, 2017] [Originally Added On: February 26th, 2017]
- Real Madrid CF slump to loss vs Valencia CF in La Liga - Hindustan Times [Last Updated On: February 26th, 2017] [Originally Added On: February 26th, 2017]
- CF Industries Holdings, Inc. (CF): What's the Story? - StockNewsJournal [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- CF-18 pilot killed at Cold Lake did not eject or make mayday call - CBC.ca [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- Get rough with Panasonic's new hybrid Toughbook - CNET [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- The Technicals For CF Industries Holdings, Inc. (CF), An Important Analysis - NY Stock News [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- The Panasonic CF-33 is a Toughbook you can tote - CNET [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- Sherby named CF mayor Falls mayor - Iron County Reporter [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- New classes at the CF Contemporary Center - Iron County Reporter [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- Comment: You know the medical definition... but how many of you ... - Irish Independent [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- Taoiseach expects deal on CF drug Orkambi in coming weeks - Irish Times [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- Matheny on CF prospect Sierra: 'He's an electric player' - STLtoday.com [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- Panasonic Toughbook CF-33 gets the 2-in-1 Windows 10 treatment - SlashGear [Last Updated On: March 2nd, 2017] [Originally Added On: March 2nd, 2017]
- PTC Therapeutics' ataluren flunks late-stage CF study; shares slump 24% premarket - Seeking Alpha [Last Updated On: March 2nd, 2017] [Originally Added On: March 2nd, 2017]
- CF to host men's and women's state hoops tournaments - Ocala [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- Tigers CF Mikie Mahtook: Expect The 2015 Version Of Me - CBS Detroit [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- SEC Report on Reg CF Crowdfunding: What Does it Mean? - Crowdfund Insider [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- Lat strain abates, Collins to rejoin CF fight soon - Detroit News - The Detroit News [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- PTC notches up full house of failures in CF with ataluren, dumps program - FierceBiotech [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- Panasonic's Toughbook CF-33 Might Be the Most Durable 2-in-1 Yet - Laptop Mag [Last Updated On: March 4th, 2017] [Originally Added On: March 4th, 2017]
- CF Industries Holdings, Inc. (CF): How Do the Technicals Stack Up? - The USA Commerce [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]